**Name of journal: World Journal of Respirology**

**ESPS Manuscript NO: 14709**

**Columns: Review**

**Collagen vascular disease-associated interstitial lung disease**

Vigeland CL *et al*. Collagen vascular disease-associated ILD

Christine L Vigeland, Maureen R Horton

**Christine L Vigeland, Maureen R Horton,** Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, United States

**Author contributions:** Vigeland CL and Horton MR contributed equally to this work.

**Conflict-of-interest:** Dr. Christine L Vigeland is an employee of the Johns Hopkins University School of Medicine. Dr. Maureen R Horton is an employee of the Johns Hopkins University School of Medicine and has received research funding from NIH, FAMRI, American Asthma Foundation, Hoffman-Roche, and InterMune.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:** **Maureen R Horton, MD**, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Fifth Floor, Baltimore, MD 21205, United States. mhorton2@jhmi.edu

**Telephone:** +1-410-6145445

**Fax:** +1-410-9550299

**Received:** October 20, 2014

**Peer-review started:** October 21, 2014

**First decision:** November 27, 2014

**Revised:** December 19, 2014

**Accepted:** March 4, 2015

**Article in press:**

**Published online:**

**Abstract**

Interstitial lung disease (ILD) is an important manifestation of collagen vascular diseases. It is a common feature of scleroderma, and also occurs in dermatomyositis and polymyositis, mixed connective tissue disease, Sjogren’s syndrome, rheumatoid arthritis, systemic lupus erythematosus, and ANCA-associated vasculitis. When present, it is associated with increased morbidity and mortality, thus making early diagnosis important. In fact, in many patients, ILD may be the first manifestation of a collagen vascular disease. The most common symptoms are cough and dyspnea. The diagnosis is made based on pulmonary function tests showing restrictive lung disease and impaired oxygen diffusion and chest imaging showing ground glass infiltrates, interstitial thickening, and/or fibrosis. The most common histologic finding on lung biopsy is non-specific interstitial pneumonia, though organizing pneumonia and usual interstitial pneumonia may also be seen. Treatment is focused on addressing the underlying collagen vascular disease with immunosuppresion, either with corticosteroids or a steroid-sparing agent such as cyclophosphamide, azathioprine, or mycophenolate, although the optimal agent and duration of therapy is not known. There are few clinical trials to guide therapy that focus specifically on the progression of ILD. The exception is in the case of scleroderma-associated ILD, where cyclophosphamide has been shown to be effective.

**Key words:** Interstitial lung disease; Collagen vascular disease; Connective tissue disease; Scleroderma; Rheumatoid arthritis; myositis; Sjogren’s syndrome; Systemic lupus erythematosus; ANCA-associated vasculitis; Mixed connective tissue disease

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Interstitial lung disease (ILD) is a significant manifestation of collagen vascular diseases due to its association with increased morbidity and mortality. Thus it is important for clinicians to consider and be able to recognize collagen vascular disease-associated ILD and initiate appropriate treatment. This review will discuss the clinical features, histologic findings, and treatment options of collagen vascular disease-associated ILD.

Vigeland CL, Horton MR. Collagen vascular disease-associated interstitial lung disease. *World J Respirol* 2015; In press

**INTRODUCTION**

Collagen vascular diseases (CVD) are a diverse group of autoimmune diseases which can have a myriad of manifestations. These include cardiac (pericarditis), musculoskeletal (myositis, inflammatory arthritis), dermatologic (rashes), ophthalmic (uveitis), and pulmonary [interstitial lung disease (ILD), pulmonary arterial hypertension]. ILD is a frequent manifestation of CVD, although the prevalence varies between each disease. ILD is most commonly seen in scleroderma, where it is found in up to 70% of patients, and least commonly in lupus where it occurs in 5%-10% of patients[1-4]. ILD may also be the initial presentation of a CVD. Based on the experience at the Johns Hopkins ILD clinic, 15% of patients presenting with a new diagnosis of ILD have an undiagnosed CVD[5]. Regardless of the associated CVD, when ILD does occur, it is associated with increased morbidity and mortality[3,4,6-14]. Thus it is critical that ILD is identified early so that treatment can be initiated. In this review, the clinical presentations, histologic features, and treatment of collagen vascular disease-associated ILD (CVD-ILD) will be discussed. A summary of the key features of CVD-ILD can be found in Table 1.

**OVERVIEW**

***Clinical presentation***

Clinically, ILD typically manifests with progressive dyspnea on exertion and dry cough. However, given the existence of concomitant joint disease and mobility issues, patients often attribute the early symptoms to the CVD or deconditioning and have frequently lost considerable lung function prior to diagnosis. CVD-ILD is diagnosed based on clinical presentation, loss of lung function and demonstration of interstitial scarring on chest imaging. Pulmonary function testing (PFT) reveals restrictive lung disease with diminished total lung capacity (TLC), decreased forced vital capacity (FVC), and impaired diffusion capacity of the lung for carbon monoxide (DLCO). Chest imaging demonstrates ground glass, inter- and intra-lobular interstitial thickening, and in many cases end stage fibrosis and scarring[15]. Imaging may also show other manifestations of the underlying CVD such as enlargement of the pulmonary artery or dilation of the esophagus [15]. Bronchoscopy is often used to rule out alternative diagnoses such as infection but is not typically diagnostic of CVD-ILD.

***Histology and imaging findings***

Lung biopsy may show a variety of histopathology, most commonly non-specific interstitial pneumonia (NSIP), though organizing pneumonia (OP) and usual interstitial pneumonia (UIP) may be present depending on the CVD[16]. However, due to the risks of the procedure, surgical lung biopsy is not routinely part of the workup of CVD-ILD. Diagnosis is based upon clinical presentation, history, PFTs and high-resolution computed tomography (HRCT) scan. The typical HRCT findings for a patient with UIP are intralobular septal thickening, honeycombing, traction bronchiectasis, and subpleural, peripheral reticular opacities[17]. In contrast, NSIP is characterized by subpleural ground glass opacities, predominantly in the lower lobes[17]. There may be interlobular septal thickening and honeycombing, but the honeycombing is typically microcystic[17]. In OP, the HRCT shows patchy, peripheral ground glass opacities or consolidations, which may be migratory[17]. Lymphoid interstitial pneumonia (LIP) is characterized by diffuse ground glass opacities with intermixed central or perivascular cysts[17].Thus, HRCT is essential in not only diagnosing CVD-ILD but also in suggesting potential histologic patterns that may alter prognosis.

Due the association between esophageal dysmotility and CVD, particularly in patients with scleroderma, there can also be evidence of chronic aspiration in the lungs. Studies have found that chronic aspiration is associated with a bronchocentric distribution of noncaseating granulomas, basophilic intraluminal contents and foreign-body containing multinucleated giant cells on histopathology[18-21]. On HRCT, patients with chronic aspiration have centrilobular nodules, tree-in-bud opacities, and bronchial wall thickening with or without fibrosis, predominantly in the lower lobes, often times with dilation of the esophagus as well[18-21].

***Treatment***

Generally speaking, treatment of CVD-ILD is focused on addressing the underlying CVD, and there are not many randomized-controlled trials looking at the ILD specifically to guide therapy. The exception to this is in the case of scleroderma-associated ILD, where studies have shown cyclophosphamide to be effective[22,23].

**FEATURES OF SPECIFIC CVD-ILD**

***Clinical presentation***

Scleroderma is a CVD with skin, cardiac, pulmonary, gastrointestinal, and renal involvement[24]. The pulmonary manifestations include pulmonary arterial hypertension and ILD[24].ILD is a significant cause of mortality in patients with scleroderma[6,7,13]. Lung involvement portends a worse prognosis, and more severe fibrosis is correlated with higher mortality[6,7,12,13]. The prevalence of pulmonary fibrosis varies between studies. When diagnosed by either restrictive physiology on PFTs or characteristic findings on HRCT scan, ILD is present in 25%-40% of patients[12,13,24,25]. However, this likely underestimates the true prevalence of disease as at autopsy, ILD is present in at least 70% of cases[1,16]. Due to its association with pulmonary arterial hypertension and esophageal dysmotility, other common findings on HRCT scan are enlargement of the pulmonary artery and dilation of the esophagus[15]. PFTs may also show evidence of pulmonary arterial hypertension with reduction in DLCO out of proportion to the reduction in TLC.

***Histology and imaging findings***

The most common histopathology pattern is NSIP. Rarely UIP or OP are seen[16,26,27]. HRCT most commonly shows confluent ground glass, a fine reticular pattern of interstitial markings, and traction bronchiectasis[15].

***Treatment***

The most established treatment for scleroderma-associated ILD is cyclophosphamide[28]. In two multicenter randomized placebo-controlled trials, treatment with cyclophosphamide for one year showed improvement in lung function[22,29]. In the Scleroderma Lung Study, cyclophosphamide was shown to improve FVC and TLC after 12 mo of therapy compared to placebo[22]. Follow up analysis of this study identified a group of patients with an enhanced response to treatment, who were characterized by more severe fibrosis at baseline based on HRCT scan and/or more severe skin involvement[23].The other study compared prednisolone plus cyclophosphamide for 6 mo followed by azathioprine and found at 12 mo a trend towards improvement in FVC[29]. Other studies have shown similar results[30-33]. One question that remains, however, is the optimal duration of treatment. The Scleroderma Lung Study found that following 12 mo of therapy, the benefit persisted 6 mo after treatment was stopped, with lung function returned to pre-treatment levels 12 mo after therapy was ended[22,23]. Additional studies with longer follow up have shown persistent stability in lung function up to 3-4 years after the end of therapy[32,34]. However, not all patients have such a prolonged benefit. One study found that 4 years after therapy, although 69% of patients had stable lung function, 32% of patients had experienced progression of their disease[32]. Due to the side effects of cyclophosphamide, other drugs have been explored for use as maintenance therapies. Azathioprine and methotrexate are commonly used as maintenance[26,33,35,36].However, concern remains of using methotrexate in patients with CVD-ILD as the drug itself may cause drug-induced-ILD that may complicate the picture.

As monotherapy, mycophenolate has also been shown in retrospective studies to stabilize lung function after at least 6 mo of therapy[37-39]. Azathioprine as monotherapy was shown to stabilize FVC and improve dyspnea after treatment for at least 12 mo in a retrospective study[40]. However, a subsequent study comparing cyclophosphamide to azathioprine showed worsening of lung function with azathioprine compared to stability of lung function with cyclophosphamide[41].

Due to the association between corticosteroids and scleroderma renal crisis, corticosteroids have been used less commonly than for other CVD-ILD.However, a retrospective cohort analysis of two medical centers in Japan showed that corticosteroid monotherapy as compared to no therapy was associated with improvement in FVC without any change in 5 or 10 year survival[42].

Another medication that has been evaluated is rituximab. Rituximab is a monoclonal antibody against B cells and has been shown in a few case reports and one randomized controlled trial of 14 patients to be associated with improvement in lung function[43].

Recently, pirfenidone has been shown in patients with idiopathic pulmonary fibrosis (IPF) to slow decline in FVC[44]. Pirfenidone has antifibrotic effects, and in mouse models of IPF has been shown to reduce pro-fibrotic cytokines such as transforming growth factor beta (TGF-β) and to inhibit fibrocyte accumulation in the lungs[45,46]. This drug is now being studied in patients with scleroderma-ILD to see if it has the same effects as in patients with IPF.

These trials have not examined responses based on histology patterns, as most patients do not require a lung biopsy to make the diagnosis. One exception is in patients who have fibrotic lung disease with predominantly features of chromic aspiration. Esophageal dysmotility, which can predispose one to chronc aspiration, is a common feature of scleroderma. One study differentiated patients with scleroderma-ILD into those with features of NSIP versus those with features of chronic aspiration based on lung biopsy, with those found to have NSIP treated with cyclophosphamide for one year and those found to have chronic aspiration treated with aggressive proton pump inhibitor therapy, prokinetic medications, and lifestyle modifications for GERD[21]. After one year of therapy, both groups had stability in their FVC, FEV1, and DLCO, suggesting that in a subset of patients with ILD related to chronic aspiration, antireflux therapy may be critical in slowing or halting disease progression[21].

**DERMATOMYOSITIS AND POLYMYOSITIS**

***Clinical presentation***

ILD is also commonly found in patients with dermatomyositis and polymyositis, and is a significant cause of mortality[9,10,14]. Studies have found that 20%-30% of patients with myositis have ILD, and ILD may precede muscle and skin findings in about 20% of patients[9,10,14,47]. There is a strong association between ILD and the presence of antisynthetase antibodies (most commonly anti-Jo-1)[9,10,47]. Because of associated muscular weakness and deconditioning, dyspnea on exertion may go unrecognized for some time. Additionally, muscular weakness can affect the diaphragm, causing a diminished TLC out of proportion to the DLCO, which is more pronounced in the supine position.

***Histology and imaging findings***

The most common histology is NSIP, but OP or UIP may also be seen[10,16,26]. HRCT typically shows confluent ground glass consolidation in the lower lobes with reticular interstitial changes and traction bronchiectasis, consistent with NSIP[15].

***Treatment***

Treatment is based on the underlying histologic pattern. Organizing pneumonia and NSIP are most responsive to steroids compared to UIP[10,26]. For those patients who do not respond to corticosteroids, retrospective studies and case series have shown stabilization or improvement in pulmonary function with the use of cyclophosphamide[47,48], mycophenolate[39,49], azathioprine[14,50], and calcineurin inhibitors[51-53]. Azathioprine and mycophenolate are also used for maintenance therapy following cyclophosphamide[10]. Case reports have also shown improvement with intravenous immunoglobulin (IVIG)[54,55].

**MIXED CONNECTIVE TISSUE DISEASE**

***Clinical presentation***

Mixed connective tissue disease (MCTD) is a unique collagen vascular disease characterized by the presence of anti-ribonucleoprotein (anti-RNP) antibodies and clinical features similar to lupus, scleroderma, and dermatomyositis/polymyositis, including myositis, sclerodactyly, Raynaud’s phenomenon, and polyarthritis[8,56,57]. ILD is present in approximately 30%-60% of patients[8,57]. As in other CVD, the presence of severe fibrosis has been associated with increased mortality[8]. In addition to ILD, MCTD is also associated with pleural thickening, pleural effusions, and pericardial effusions, all of which may be seen on HRCT scan[15].

***Histology and imaging findings***

The most common pathology seen is NSIP, with UIP and OP seen less commonly[16,26]. HRCT shows ground glass predominantly in the lower lobes[15].

***Treatment***

Similar to other CVD-ILD, therapy is guided by treatment of the underlying CVD. Corticosteroids have shown some efficacy, with one uncontrolled study showing that 50% of patients treated with corticosteroid monotherapy had improvement in lung function, and an additional 20% improving with corticosteroids plus cyclophosphamide[57].

**SJOGREN’S SYNDROME**

***Clinical presentation***

Sjogren’s syndrome is a disease primary affecting exocrine glands, with ILD representing a major extraglandular manifestion[11]. Studies have found a wide range in the prevalence of ILD, from 25%-40%[11,58-60]. As with other CVD-associated ILD, the presence of ILD is associated with poor survival[11].

***Histology and imaging findings***

The most common pathology pattern is NSIP, but UIP, OP, and LIP can be present as well[16,26,61-63]. The typical HRCT findings are consistent with NSIP, patchy ground glass and microcystic honeycombing predominantly in the lower lobes[15]. When LIP is present, the HRCT shows ground glass, cysts (5-30 mm), and pericbronchovesicular, centriblobular, and subpleural nodules[15]. Other findings that can be seen patients with Sjogren’s syndrome in general are bronchial wall thickening, bronchiectasis, air trapping, cysts, and nodules[15].

***Treatment***

Corticosteroids are the primary treatment, with case series showing the majority of patients improving with this therapy[61]. There are also reports of corticosteroid and cyclophosphamide used with the majority of patients demonstrating improvement or stabilization of lung function[63].

**RHEUMATOID ARTHRITIS**

***Clinical presentation***

ILD is the most common pulmonary manifestation of rheumatoid arthritis (RA), affecting approximately 10%-20% of patients[3,4,64-66]. Development of ILD is associated with increased mortality[3,4]. Although most patients with rheumatoid arthritis are women, male gender confers an increased risk of developing ILD[64,67,68]. Smoking, anti-citrullinated protein (anti-CCP) antibodies, and rheumatoid factor (RF) antibodies have also all been associated with an increased risk of developing ILD[3,68,69].In addition to ILD, pulmonary manifestations of rheumatoid arthritis include pulmonary arterial hypertension, necrobiotic nodules, and obliterative bronchiolitis, and thus HRCT may show enlargement of the pulmonary artery, mosaic attenuation with air trapping, and/or pulmonary nodules[15].On PFTs, reduction in DLCO out of proportion to the reduction of TLC suggests the presence of pulmonary arterial hypertension as well. There also may be obstruction if there is concomitant airways disease.

Drugs used to treat RA have also been associated with pulmonary toxicity, and it is important to differentiate between drug-induced lung disease and RA-ILD. Agents known to cause pulmonary toxicity include methotrexate, gold, penicillamine, leflunamide, and anti-tumor necrosis factor alpha (anti-TNF-α) agents[65,70-72]. Indeed, biologic agents, specifically anti-TNF-α agents have been associated with both new and exacerbation of underlying ILD[73]. Increased mortality rates in up to two-thirds of patients with existing ILD were reported[73]. It is unclear if the drugs caused the worsening ILD or that the patients had underlying aggressive disease necessitating use of more aggressive ILD therapy with biologic agents.Drug-induced pulmonary toxicity should be suspected based on the timing of symptoms and use of a suspect medication. Labs may or may not be helpful. In the case of penicillamine, patients develop a peripheral eosinophilia, but in the case of other drugs, labs and BAL findings are nonspecific[72]. The treatment is to stop the offending agent and in severe cases start steroids.

***Histology and imaging findings***

Unlike the other CVD, UIP is the most common histopathology, though NSIP can also be seen[16,26,71]. The UIP pattern is associated with an increased mortality and a poor response to therapy compared to the NSIP pattern[68,74].However, the prognosis with a UIP pattern associated with rheumatoid arthritis is less severe than in patients with IPF[74]. HRCT findings in RA-ILD are most commonly a UIP pattern, similar to IPF, with basal predominant, subpleural, peripheral distribution of interstitial fibrosis and honeycombing[15]. Given that it does not change management, surgical lung biopsy is not typically performed to differentiate between UIP and NSIP.

***Treatment***

For patients with NSIP and OP pathology, corticosteroids are first line therapy[71,75]. However, UIP has not been shown to be steroid responsive[71]. Typically patients are treated with a combination of corticosteroids and cyclophosphamide, or corticosteroids and azathioprine, though there are not studies to evaluate the efficacy of these regimens[70]. Medications used for RA that are associated with causing lung injury or worsening ILD should be avoided[70]. As noted above, due to concerns with anti-TNF-α either initiating or exacerbating ILD, there have yet to be any clinical trials evaluating use of biologic anti-TNF-α agents to treat RA-ILD.

**SYSTEMIC LUPUS ERYTHEMATOSUS**

***Clinical presentation***

Systemic lupus erythematosus (SLE) can have a variety of pulmonary manifestations, including pleuritis with or without a pleural effusion, pulmonary arterial hypertension, thromboembolic disease, and diaphragmatic weakness[76].ILD is a rare manifestation of lupus, occurring in approximately 5%-10% of patients[2]. However, this number may underestimate the true prevalence, as an autopsy study revealed a prevalence of approximately 15%[77]. Other studies have found evidence of ILD on HRCT in up to 30% of patients[78].

SLE patients can also develop an acute pneumonitis, characterized by acute onset of fever, dyspnea, cough, and pleuritic chest pain[76,78]. HRCT shows diffuse ground glass and consolidations[15,76,78]. Patients with acute pneumonitis are critically ill, and there is a high mortality rate. Treatment is based on case reports, and high dose corticosteroids are most commonly used[76].

***Histology and imaging findings***

SLE-ILD is associated with an NSIP or OP pattern[16,26]. HRCT shows subpleural ground glass opacities, or patchy consolidation and air bronchograms consistent with NSIP or OP respectively[15].

***Treatment***

There are no placebo-controlled trials to guide treatment for lupus-associated ILD[76,78]. Corticosteroids have been used with some efficacy in slowing or improving ILD[2]. Other immunosuppressants such as azathioprine and intravenous cyclophosphamide have also been used[76].

**ANCA-ASSOCIATED VASCULITIS**

***Clinical presentation***

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are pauci-immune vasculitides that includes granulomatosis with polyangitis (GPA, formerly called Wegener’s granulomatosis), microscopic polyangitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGP, formerly called Churg-Strauss syndrome). These conditions, particularly MPA, have been associated with ILD. Studies have found the prevalence of ILD in patients with MPA to range from 7%-47% of patients[79-81]. The presence of myeloperoxidase-ANCA (MPO-ANCA) rather than proteinase 3-ANCA (PR3-ANCA) is associated with ILD[80]. Other pulmonary manifestations of AAV are pulmonary hemorrhage, pulmonary nodules, and tracheobronchial stenosis or masses[79, 81]. Asthma is also a feature of EGP.

***Histology and imaging findings***

On histology, the most common pattern is UIP, with NSIP also seen, as well as vasculitis of bronchial and pulmonary arterioles[82]. HRCT typically shows a UIP or NSIP pattern, with thickened interlobular septa, honeycombing, traction bronchiectasis and ground glass infiltrates[79,81,82].

***Treatment***

The mainstay of treatment of ANCA-associated vasculitis is induction therapy with either cyclophosphamide and prednisone or rituximab and prednisone, followed by maintenance with methotrexate or azathioprine[83-87]. Plasmapheresis is used only for patients with severe pulmonary hemorrhage[87].

**CONCLUSION**

ILD is a manifestation of CVD that causes significant morbidity and mortality. It typically presents with dyspnea and cough, though due to other symptoms such as systemic weakness and deconditioning, symptoms may become apparent only after significant lung function has been lost. The most common histology is NSIP, although OP and UIP are also seen[16]. UIP is most commonly seen in RA-ILD and AAV-ILD and is associated with less response to treatment and worse prognosis compared to NSIP[16,26,71,82]. In terms of therapy, the only randomized-controlled trials are in patients with scleroderma-associated ILD, where cyclophosphamide has been shown to be effective in halting progression of disease[22,29]. For other CVD-ILD, therapy is targeted at controlling the underlying CVD, most commonly with steroids, cyclophosphamide, mycophenolate, and azathioprine. Given the significant morbidity and mortality associated with CVD-ILD, future studies are needed to evaluate the optimal therapy for these diseases. Additionally, it is important to explore the pathogenesis underlying development of ILD in order to provide future targets for new therapies.

**REFERENCES**

1 **D'Angelo WA**, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. *Am J Med* 1969; **46**: 428-440 [PMID: 5780367 DOI: 10.1016/0002-9343(69)90044-8]

2 **Weinrib L**, Sharma OP, Quismorio FP. A long-term study of interstitial lung disease in systemic lupus erythematosus. *Semin Arthritis Rheum* 1990; **20**: 48-56 [PMID: 2218553 DOI: 10.1016/0049-0172(90)90094-V]

3 **Bongartz T**, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2010; **62**: 1583-1591 [PMID: 20155830 DOI: 10.1002/art.27405]

4 **Olson AL**, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, Murphy J, Cohen M, Raghu G, Brown KK. Rheumatoid arthritis-interstitial lung disease-associated mortality. *Am J Respir Crit Care Med* 2011; **183**: 372-378 [PMID: 20851924 DOI: 10.1164/rccm.201004-0622OC]

5 **Mittoo S**, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. *Respir Med* 2009; **103**: 1152-1158 [PMID: 19304475 DOI: 10.1016/j.rmed.2009.02.009]

6 **Ferri C**, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. *Medicine (Baltimore)* 2002; **81**: 139-153 [PMID: 11889413 DOI: 10.1097/00005792-200203000-00004]

7 **Goh NS**, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, Bozovic G, Denton CP, Black CM, du Bois RM, Wells AU. Interstitial lung disease in systemic sclerosis: a simple staging system. *Am J Respir Crit Care Med* 2008; **177**: 1248-1254 [PMID: 18369202 DOI: 10.1164/rccm.200706-877OC]

8 **Gunnarsson R**, Aaløkken TM, Molberg Ø, Lund MB, Mynarek GK, Lexberg AS, Time K, Dhainaut AS, Bertelsen LT, Palm O, Irgens K, Becker-Merok A, Nordeide JL, Johnsen V, Pedersen S, Prøven A, Garabet LS, Gran JT. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. *Ann Rheum Dis* 2012; **71**: 1966-1972 [PMID: 22550317 DOI: 10.1136/annrheumdis-2011-201253]

9 **Marie I**, Hachulla E, Chérin P, Dominique S, Hatron PY, Hellot MF, Devulder B, Herson S, Levesque H, Courtois H. Interstitial lung disease in polymyositis and dermatomyositis. *Arthritis Rheum* 2002; **47**: 614-622 [PMID: 12522835 DOI: 10.1002/art.10794]

10 **Marie I**, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. *Arthritis Rheum* 2011; **63**: 3439-3447 [PMID: 21702020 DOI: 10.1002/art.30513]

11 **Nannini C**, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL. Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. *BMJ Open* 2013; **3**: e003569 [PMID: 24282246 DOI: 10.1136/bmjopen-2013-003569]

12 **Simeón CP**, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, Lima J, Vaqué J, Vilardell M. Mortality and prognostic factors in Spanish patients with systemic sclerosis. *Rheumatology (Oxford)* 2003; **42**: 71-75 [PMID: 12509616 DOI: 10.1093/rheumatology/keg033]

13 **Steen VD**, Conte C, Owens GR, Medsger TA. Severe restrictive lung disease in systemic sclerosis. *Arthritis Rheum* 1994; **37**: 1283-1289 [PMID: 7945490 DOI: 10.1002/art.1780370903]

14 **Yu KH**, Wu YJ, Kuo CF, See LC, Shen YM, Chang HC, Luo SF, Ho HH, Chen IJ. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. *Clin Rheumatol* 2011; **30**: 1595-1601 [PMID: 21915609 DOI: 10.1007/s10067-011-1840-0]

15 **Lynch DA**. Lung disease related to collagen vascular disease. *J Thorac Imaging* 2009; **24**: 299-309 [PMID: 19935226 DOI: 10.1097/RTI.0b013e3181c1acec]

16 **Tansey D**, Wells AU, Colby TV, Ip S, Nikolakoupolou A, du Bois RM, Hansell DM, Nicholson AG. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. *Histopathology* 2004; **44**: 585-596 [PMID: 15186274 DOI: 10.1111/j.1365-2559.2004.01896.x]

17 **Argiriadi PA**, Mendelson DS. High resolution computed tomography in idiopathic interstitial pneumonias. *Mt Sinai J Med* 2009; **76**: 37-52 [PMID: 19170217 DOI: 10.1002/msj.20089]

18 **Barnes TW**, Vassallo R, Tazelaar HD, Hartman TE, Ryu JH. Diffuse bronchiolar disease due to chronic occult aspiration. *Mayo Clin Proc* 2006; **81**: 172-176 [PMID: 16471070 DOI: 10.4065/81.2.172]

19 **Cardasis JJ**, MacMahon H, Husain AN. The spectrum of lung disease due to chronic occult aspiration. *Ann Am Thorac Soc* 2014; **11**: 865-873 [PMID: 24950025 DOI: 10.1513/AnnalsATS.201310-360OC]

20 **de Carvalho ME**, Kairalla RA, Capelozzi VL, Deheinzelin D, do Nascimento Saldiva PH, de Carvalho CR. Centrilobular fibrosis: a novel histological pattern of idiopathic interstitial pneumonia. *Pathol Res Pract* 2002; **198**: 577-583 [PMID: 12440779 DOI: 10.1078/0344-0338-00305]

21 **de Souza RB**, Borges CT, Capelozzi VL, Parra ER, Jatene FB, Kavakama J, Kairalla RA, Bonfá E. Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis. *Respiration* 2009; **77**: 389-397 [PMID: 18799868 DOI: 10.1159/000156958]

22 **Tashkin DP**, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M. Cyclophosphamide versus placebo in scleroderma lung disease. *N Engl J Med* 2006; **354**: 2655-2666 [PMID: 16790698 DOI: 10.1056/NEJMoa055120]

23 **Roth MD**, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, Khanna D, Kleerup EC, Li N, Elashoff D, Elashoff RM. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. *Arthritis Rheum* 2011; **63**: 2797-2808 [PMID: 21547897 DOI: 10.1002/art.30438]

24 **Owens GR**, Fino GJ, Herbert DL, Steen VD, Medsger TA, Pennock BE, Cottrell JJ, Rodnan GP, Rogers RM. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. *Chest* 1983; **84**: 546-550 [PMID: 6628005 DOI: 10.1378/chest.84.5.546]

25 **Scussel-Lonzetti L**, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, Raymond Y, Senécal JL. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. *Medicine (Baltimore)* 2002; **81**: 154-167 [PMID: 11889414 DOI: 10.1097/00005792-200203000-00005]

26 **Maher TM**. Immunosuppression for connective tissue disease-related pulmonary disease. *Semin Respir Crit Care Med* 2014; **35**: 265-273 [PMID: 24668541 DOI: 10.1055/s-0034-1371531]

27 **Bouros D**, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. *Am J Respir Crit Care Med* 2002; **165**: 1581-1586 [PMID: 12070056 DOI: 10.1164/rccm.2106012]

28 **Walker KM**, Pope J. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. *J Rheumatol* 2011; **38**: 1326-1328 [PMID: 21459952 DOI: 10.3899/jrheum.101262]

29 **Hoyles RK**, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. *Arthritis Rheum* 2006; **54**: 3962-3970 [PMID: 17133610 DOI: 10.1002/art.22204]

30 **White B**, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. *Ann Intern Med* 2000; **132**: 947-954 [PMID: 10858177 DOI: 10.7326/0003-4819-132-12-200006200-00004]

31 **Poormoghim H**, Moradi Lakeh M, Mohammadipour M, Sodagari F, Toofaninjed N. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. *Rheumatol Int* 2012; **32**: 2431-2444 [PMID: 21691743 DOI: 10.1007/s00296-011-1967-y]

32 **Mittoo S**, Wigley FM, Wise RA, Woods A, Xiao H, Hummers LK. Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease. *Open Rheumatol J* 2011; **5**: 1-6 [PMID: 21552414 DOI: 10.2174/1874312901105010001]

33 **Paone C**, Chiarolanza I, Cuomo G, Ruocco L, Vettori S, Menegozzo M, La Montagna G, Valentini G. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. *Clin Exp Rheumatol* 2007; **25**: 613-616 [PMID: 17888219]

34 **Domiciano DS**, Bonfá E, Borges CT, Kairalla RA, Capelozzi VL, Parra E, Christmann RB. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. *Clin Rheumatol* 2011; **30**: 223-229 [PMID: 20544245 DOI: 10.1007/s10067-010-1493-4]

35 **Bérezné A**, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J, Cohen P, Mahr A, Pagnoux C, Hachulla E, Kahan A, Cabane J, Guillevin L, Mouthon L. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. *J Rheumatol* 2008; **35**: 1064-1072 [PMID: 18464307]

36 **Walker KM**, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. *Semin Arthritis Rheum* 2012; **42**: 42-55 [PMID: 22464314 DOI: 10.1016/j.semarthrit.2012.01.003]

37 **Koutroumpas A**, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. *Clin Rheumatol* 2010; **29**: 1167-1168 [PMID: 20532938 DOI: 10.1007/s10067-010-1498-z]

38 **Gerbino AJ**, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. *Chest* 2008; **133**: 455-460 [PMID: 18071023 DOI: 10.1378/chest.06-2861]

39 **Swigris JJ**, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, Meehan RT, Brown KK. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. *Chest* 2006; **130**: 30-36 [PMID: 16840379]

40 **Dheda K**, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. *Clin Rheumatol* 2004; **23**: 306-309 [PMID: 15293090]

41 **Nadashkevich O**, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. *Clin Rheumatol* 2006; **25**: 205-212 [PMID: 16228107]

42 **Ando K**, Motojima S, Doi T, Nagaoka T, Kaneko N, Aoshima M, Takahashi K. Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. *Respir Investig* 2013; **51**: 69-75 [PMID: 23790734 DOI: 10.1016/j.resinv.2012.12.002]

43 **Daoussis D**, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P, Yiannopoulos G, Andonopoulos AP. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. *Semin Arthritis Rheum* 2010; **40**: 127-136 [PMID: 20004954 DOI: 10.1016/j.semarthrit.2009.09.003]

44 **King TE**, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med* 2014; **370**: 2083-2092 [PMID: 24836312]

45 **Oku H**, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. *Eur J Pharmacol* 2008; **590**: 400-408 [PMID: 18598692 DOI: 10.1016/j.ejphar.2008.06.046]

46 **Inomata M**, Kamio K, Azuma A, Matsuda K, Kokuho N, Miura Y, Hayashi H, Nei T, Fujita K, Saito Y, Gemma A. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. *Respir Res* 2014; **15**: 16 [PMID: 24507087 DOI: 10.1186/1465-9921-15-16]

47 **Schnabel A**, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. *Semin Arthritis Rheum* 2003; **32**: 273-284 [PMID: 12701038 DOI: 10.1053/sarh.2002.50012]

48 **Yamasaki Y**, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, Kurihara Y, Osada H, Satoh M, Ozaki S. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. *Rheumatology (Oxford)* 2007; **46**: 124-130 [PMID: 16754626 DOI: 10.1093/rheumatology/kel112]

49 **Morganroth PA**, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. *Arthritis Care Res (Hoboken)* 2010; **62**: 1496-1501 [PMID: 20506189 DOI: 10.1002/acr.20212]

50 **Mok CC**, To CH, Szeto ML. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. *Scand J Rheumatol* 2003; **32**: 181-183 [PMID: 12892257 DOI: 10.1080/03009740310002542]

51 **Nawata Y**, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, Kita Y, Kawai M, Saito Y, Iwamoto I. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. *J Rheumatol* 1999; **26**: 1527-1533 [PMID: 10405940]

52 **Labirua-Iturburu A**, Selva-O'Callaghan A, Martínez-Gómez X, Trallero-Araguás E, Labrador-Horrillo M, Vilardell-Tarrés M. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. *Clin Exp Rheumatol* 2013; **31**: 436-439 [PMID: 23465087]

53 **Cavagna L**, Caporali R, Abdì-Alì L, Dore R, Meloni F, Montecucco C. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. *J Rheumatol* 2013; **40**: 484-492 [PMID: 23418387 DOI: 10.3899/jrheum.121026]

54 **Suzuki Y**, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, Suda T, Chida K. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. *Lung* 2009; **187**: 201-206 [PMID: 19387736 DOI: 10.1007/s00408-009-9146-6]

55 **Bakewell CJ**, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. *Chest* 2011; **139**: 441-443 [PMID: 21285059 DOI: 10.1378/chest.10-0360]

56 **Prakash UB**. Respiratory complications in mixed connective tissue disease. *Clin Chest Med* 1998; **19**: 733-746, ix [PMID: 9917963]

57 **Bodolay E**, Szekanecz Z, Dévényi K, Galuska L, Csípo I, Vègh J, Garai I, Szegedi G. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). *Rheumatology (Oxford)* 2005; **44**: 656-661 [PMID: 15716315 DOI: 10.1093/rheumatology/keh575]

58 **Franquet T**, Giménez A, Monill JM, Díaz C, Geli C. Primary Sjögren's syndrome and associated lung disease: CT findings in 50 patients. *AJR Am J Roentgenol* 1997; **169**: 655-658 [PMID: 9275871 DOI: 10.2214/ajr.169.3.9275871]

59 **Strimlan CV**, Rosenow EC, Divertie MB, Harrison EG. Pulmonary manifestations of Sjögren's syndrome. *Chest* 1976; **70**: 354-361 [PMID: 989035 DOI: 10.1378/chest.70.3.354]

60 **Constantopoulos SH**, Papadimitriou CS, Moutsopoulos HM. Respiratory manifestations in primary Sjögren's syndrome. A clinical, functional, and histologic study. *Chest* 1985; **88**: 226-229 [PMID: 4017677 DOI: 10.1378/chest.88.2.226]

61 **Parambil JG**, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjögren syndrome. *Chest* 2006; **130**: 1489-1495 [PMID: 17099028 DOI: 10.1378/chest.130.5.1489]

62 **Enomoto Y**, Takemura T, Hagiwara E, Iwasawa T, Fukuda Y, Yanagawa N, Sakai F, Baba T, Nagaoka S, Ogura T. Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases. *PLoS One* 2013; **8**: e73774 [PMID: 24040065 DOI: 10.1371/journal.pone.0073774]

63 **Shi JH**, Liu HR, Xu WB, Feng RE, Zhang ZH, Tian XL, Zhu YJ. Pulmonary manifestations of Sjögren's syndrome. *Respiration* 2009; **78**: 377-386 [PMID: 19390161 DOI: 10.1159/000214841]

64 **Gabbay E**, Tarala R, Will R, Carroll G, Adler B, Cameron D, Lake FR. Interstitial lung disease in recent onset rheumatoid arthritis. *Am J Respir Crit Care Med* 1997; **156**: 528-535 [PMID: 9279235 DOI: 10.1164/ajrccm.156.2.9609016]

65 **Demedts M**, Wells AU, Antó JM, Costabel U, Hubbard R, Cullinan P, Slabbynck H, Rizzato G, Poletti V, Verbeken EK, Thomeer MJ, Kokkarinen J, Dalphin JC, Taylor AN. Interstitial lung diseases: an epidemiological overview. *Eur Respir J Suppl* 2001; **32**: 2s-16s [PMID: 11816822]

66 **Dawson JK**, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. *Thorax* 2001; **56**: 622-627 [PMID: 11462065 DOI: 10.1136/thorax.56.8.622]

67 **Sokka T**, Kautiainen H, Toloza S, Mäkinen H, Verstappen SM, Lund Hetland M, Naranjo A, Baecklund E, Herborn G, Rau R, Cazzato M, Gossec L, Skakic V, Gogus F, Sierakowski S, Bresnihan B, Taylor P, McClinton C, Pincus T. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. *Ann Rheum Dis* 2007; **66**: 1491-1496 [PMID: 17412740 DOI: 10.1136/ard.2006.069252]

68 **Kelly CA**, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, Dawson J, Sathi N, Ahmad Y, Koduri G, Young A. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. *Rheumatology (Oxford)* 2014; **53**: 1676-1682 [PMID: 24758887 DOI: 10.1093/rheumatology/keu165]

69 **Yin Y**, Liang D, Zhao L, Li Y, Liu W, Ren Y, Li Y, Zeng X, Zhang F, Tang F, Shan G, Zhang X. Anti-cyclic citrullinated Peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. *PLoS One* 2014; **9**: e92449 [PMID: 24743261 DOI: 10.1371/journal.pone.0092449]

70 **Kelly C**, Saravanan V. Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. *Expert Opin Pharmacother* 2008; **9**: 3221-3230 [PMID: 19040342 DOI: 10.1517/14656560802591430]

71 **O'Dwyer DN**, Armstrong ME, Cooke G, Dodd JD, Veale DJ, Donnelly SC. Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD). *Eur J Intern Med* 2013; **24**: 597-603 [PMID: 23916467 DOI: 10.1016/j.ejim.2013.07.004]

72 **Antin-Ozerkis D**, Evans J, Rubinowitz A, Homer RJ, Matthay RA. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med* 2010; **31**: 451-478 [PMID: 20692539 DOI: 10.1016/j.ccm.2010.04.003]

73 **Perez-Alvarez R**, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, Brito-Zeron P, Bosch X, Ramos-Casals M. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. *Semin Arthritis Rheum* 2011; **41**: 256-264 [PMID: 21277618 DOI: 10.1016/j.semarthrit.2010.11.002]

74 **Marigliano B**, Soriano A, Margiotta D, Vadacca M, Afeltra A. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. *Autoimmun Rev* 2013; **12**: 1076-1084 [PMID: 23684699 DOI: 10.1016/j.autrev.2013.05.001]

75 **Vassallo R**, Thomas CF. Advances in the treatment of rheumatic interstitial lung disease. *Curr Opin Rheumatol* 2004; **16**: 186-191 [PMID: 15103243 DOI: 10.1097/00002281-200405000-00004]

76 **Pego-Reigosa JM**, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. *Best Pract Res Clin Rheumatol* 2009; **23**: 469-480 [PMID: 19591778 DOI: 10.1016/j.berh.2009.01.002]

77 **Haupt HM**, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. *Am J Med* 1981; **71**: 791-798 [PMID: 7304651 DOI: 10.1016/0002-9343(81)90366-1]

78 **Swigris JJ**, Fischer A, Gillis J, Meehan RT, Brown KK. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. *Chest* 2008; **133**: 271-280 [PMID: 18187752 DOI: 10.1378/chest.07-0079]

79 **Arulkumaran N**, Periselneris N, Gaskin G, Strickland N, Ind PW, Pusey CD, Salama AD. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. *Rheumatology (Oxford)* 2011; **50**: 2035-2043 [PMID: 21873269 DOI: 10.1093/rheumatology/ker236]

80 **Sada KE**, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, Ito S, Yamada H, Wada T, Hirahashi J, Arimura Y, Makino H. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. *Arthritis Res Ther* 2014; **16**: R101 [PMID: 24758294 DOI: 10.1186/ar4550]

81 **Homma S,** Suzuki A, Sato K. Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist. *Clin Exp Nephrol* 2013; **17:** 667-71 [DOI: 10.1007/s10157-012-0710-7]

82 **Homma S**, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. *Respirology* 2004; **9**: 190-196 [PMID: 15182268 DOI: 10.1111/j.1440-1843.2004.00581.x]

83 **Fauci AS**, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. *Ann Intern Med* 1983; **98**: 76-85 [PMID: 6336643 DOI: 10.7326/0003-4819-98-1-76]

84 **Hoffman GS**, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* 1992; **116**: 488-498 [PMID: 1739240 DOI: 10.7326/0003-4819-116-6-488]

85 **Silverstone A**. Surgical treatment of vulval carcinoma. *Br J Hosp Med* 1989; **41**: 68-72 [PMID: 2647199 DOI: 10.1056/NEJMoa0909905]

86 **Jones RB**, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 2010; **363**: 211-220 [PMID: 20647198 DOI: 10.1056/NEJMoa0909169]

87 **Zand L**, Specks U, Sethi S, Fervenza FC. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities. *Adv Chronic Kidney Dis* 2014; **21**: 182-193 [PMID: 24602467 DOI: 10.1053/j.ackd.2014.01.009]

**P-Reviewer:** Caleiro MTC, Wu S **S-Editor:** Song XX **L-Editor:** **E-Editor:**

**Table 1 Summary of key features of collagen vascular-interstitial lung disease**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Prevalence | Histology | Other Pulmonary Findings | Treatment |
| Scleroderma | > 70% | NSIP | Pulmonary arterial hypertension | Cyclophosphamide1[22,29]Mycophenolate, azathioprine used for maintenance |
| Dermatomyositis / Polymyositis | 20%-30% | NSIP | Diaphragmatic weakness | CorticosteroidsAzathioprineMycophenolateCalcineurin inhibitorsRituximabIVIG |
| Mixed Connective Tissue Disease | 30%-60% | NSIP | Diaphragmatic weakness | Corticosteroids ± cyclophosphamide |
| Sjogren Syndrome | 25%-40% | NSIP, UIP, OP, LIP |  | Corticosteroids ± cyclophosphamide |
| Rheumatoid Arthritis | 10%-20% | UIP | May have obstructive lung disease,necrobiotic nodules, pulmonary arterial hypertension | Corticosteroids ± cyclophosphamide or azathioprine |
| Systemic Lupus Erytematosus | 5% | NSIP, OP | Pulmonary arterial hypertension,Pleural effusion | Corticosteroids ± cyclophosphamide or azathioprine  |
| ANCA-associated Vasculitis | 7%-47% | UIP | Pulmonary hemorrhage | Induction with corticosteroids + cyclophosphamide or rituximab[84-86]Maintenance with methotrexate or azathioprinePlasmapheresis for pulmonary hemorrhage |

1Use in collagen vascular disease-associated- interstitial lung disease supported by multicenter clinical trials.